Protalix BioTherapeutics Inc

Protalix BioTherapeutics reports Q1 2026 earnings: $78‑83 M revenue guidance, $25 M Elfabrio milestone, Phase‑2 PRX‑115 progress, and a focus on rare renal disease growth.

Protalix BioTherapeutics: plant‑cell tech, €CHMP approval for Elfabrio and solid NYSE American performance, showing growth in rare‑disease biotech.

Protalix BioTherapeutics seeks a new Elfabrio® dosing schedule while navigating investor concerns and a fraud probe, balancing rare‑disease growth with governance scrutiny.

Protalix BioTherapeutics Inc. reports a 16% increase in revenues to $15.4 million in Q2 2025, driven by strong sales of Elfabrio in the Fabry disease market.